Your browser doesn't support javascript.
loading
Exosome-carried microRNA-based signature as a cellular trigger for the evolution of chronic lymphocytic leukemia into Richter syndrome.
Jurj, Ancuta; Pop, Laura; Petrushev, Bobe; Pasca, Sergiu; Dima, Delia; Frinc, Ioana; Deak, Dalma; Desmirean, Minodora; Trifa, Adrian; Fetica, Bogdan; Gafencu, Grigore; Selicean, Sonia; Moisoiu, Vlad; Micu, Wilhelm-Thomas; Berce, Cristian; Sacu, Alexandra; Moldovan, Alin; Colita, Andrei; Bumbea, Horia; Tanase, Alina; Dascalescu, Angela; Zdrenghea, Mihnea; Stiufiuc, Rares; Leopold, Nicolae; Tetean, Romulus; Burzo, Emil; Tomuleasa, Ciprian; Berindan-Neagoe, Ioana.
Afiliação
  • Jurj A; a Research Center for Functional Genomic, Biomedicine and Translational Medicine , Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca , Romania.
  • Pop L; a Research Center for Functional Genomic, Biomedicine and Translational Medicine , Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca , Romania.
  • Petrushev B; b Department of Pathology , Ion Chiricuta Oncology Institute , Cluj Napoca , Romania.
  • Pasca S; a Research Center for Functional Genomic, Biomedicine and Translational Medicine , Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca , Romania.
  • Dima D; c Department of Hematology , Ion Chiricuta Oncology Institute , Cluj Napoca , Romania.
  • Frinc I; c Department of Hematology , Ion Chiricuta Oncology Institute , Cluj Napoca , Romania.
  • Deak D; c Department of Hematology , Ion Chiricuta Oncology Institute , Cluj Napoca , Romania.
  • Desmirean M; d Department of Hematology , Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca , Romania.
  • Trifa A; c Department of Hematology , Ion Chiricuta Oncology Institute , Cluj Napoca , Romania.
  • Fetica B; b Department of Pathology , Ion Chiricuta Oncology Institute , Cluj Napoca , Romania.
  • Gafencu G; a Research Center for Functional Genomic, Biomedicine and Translational Medicine , Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca , Romania.
  • Selicean S; a Research Center for Functional Genomic, Biomedicine and Translational Medicine , Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca , Romania.
  • Moisoiu V; a Research Center for Functional Genomic, Biomedicine and Translational Medicine , Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca , Romania.
  • Micu WT; a Research Center for Functional Genomic, Biomedicine and Translational Medicine , Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca , Romania.
  • Berce C; e Center for Experimental Medicine , Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca , Romania.
  • Sacu A; d Department of Hematology , Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca , Romania.
  • Moldovan A; a Research Center for Functional Genomic, Biomedicine and Translational Medicine , Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca , Romania.
  • Colita A; f Department of Hematology , Carol Davilla University of Medicine and Pharmacy , Bucharest , Romania.
  • Bumbea H; g Department of Hematology , Coltea Hospital , Bucharest , Romania.
  • Tanase A; f Department of Hematology , Carol Davilla University of Medicine and Pharmacy , Bucharest , Romania.
  • Dascalescu A; h Department of Hematology , University Hospital , Bucharest , Romania.
  • Zdrenghea M; h Department of Hematology , University Hospital , Bucharest , Romania.
  • Stiufiuc R; i Department of Hematology , Fundeni Clinical Hospital , Bucharest , Romania.
  • Leopold N; j Department of Hematology , Grigore T. Popa University of Medicine and Pharmacy , Iasi , Romania.
  • Tetean R; k Department of Hematology , Regional Institute of Oncology , Iasi , Romania.
  • Burzo E; d Department of Hematology , Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca , Romania.
  • Tomuleasa C; d Department of Hematology , Iuliu Hatieganu University of Medicine and Pharmacy , Cluj Napoca , Romania.
  • Berindan-Neagoe I; l Department of Physics , Babes Bolyai University , Cluj Napoca , Romania.
Crit Rev Clin Lab Sci ; 55(7): 501-515, 2018 11.
Article em En | MEDLINE | ID: mdl-30238808
ABSTRACT
Even if considered a cumulative and not a proliferative CD5+ B-cell neoplasm, chronic lymphocytic leukemia (CLL) has a proliferation rate higher than that recognized earlier, especially in the lymphoid tissues. Some patients with CLL develop a clinical syndrome entitled Richter syndrome (RS). Understanding CLL genetics and epigenetics may help to elucidate the molecular basics of the clinical heterogeneity of this type of malignancy. In the present project we aimed to identify a microRNA species that can predict the evolution of therapy-resistant CLL towards RS. In the first phase of our study, microRNA-19b was identified as a possible target, and in the second phase, we transfected three different CLL cell lines with microRNA-19b mimic and inhibitor and assessed the potential role on leukemia cells in vitro. The mechanism by which miR-19b acts were identified as the upregulation of Ki67 and downregulation of p53. This was further supported through RT-PCR and western blotting on CLL cell lines, as well as by next generation sequencing on two patients diagnosed with CLL that evolved into RS.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B / Transformação Celular Neoplásica / MicroRNAs / Exossomos Tipo de estudo: Prognostic_studies Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B / Transformação Celular Neoplásica / MicroRNAs / Exossomos Tipo de estudo: Prognostic_studies Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article